Company Overview and News

Serba Dinamik, Globaltec, Barakah Offshore, Nextgreen, Sapura Energy, Wegmans and Bumi Armada

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): Based on corporate announcements and news flow today, stocks in focus on Wednesday (Oct 17) may include: Serba Dinamik Holdings Bhd, Globaltec Formation Bhd, Barakah Offshore Petroleum Bhd, Nextgreen Global Bhd, Sapura Energy Bhd, Wegmans Holdings Bhd and Bumi Armada Bhd.
7251 BRDBF 5220 5210

Globaltec scraps collaboration plan with Hong Kong's EPI Energy

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): Globaltec Formation Bhd has aborted its plan to collaborate with Hong Kong's EPI Energy Holdings Ltd to participate in the exploration and production activities of Globaltec's Indonesian unit.

KLCI pares gains as sellers outpace buyers

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819

KLCI reverses loss, tracks modest regional gains

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI reversed its earlier losses and climbed at mid-morning, tracking the modest rise at the regional markets.
UPBMF 5220 7113 5681 TPGVF BATS 4162 2291 2089 5014 7066 0131 6033 7123 5199 TGLVY 4588 PNADF 0026 MYPRY HIPEF PNAGF GEBHF

Bursa Malaysia lower at mid-day

2018-10-10 malaymail
KUALA LUMPUR, Oct 10 ― Bursa Malaysia ended the morning session sharply lower on broad selling activities in the market.
5238 PNADF PBLOF 5220 1295 BSMAF HIPEF PNAGF GEBHF 6033 1818 5199

Globaltec falls 11% on 20-to-1 share consolidation, free warrants

KUALA LUMPUR: Globaltec Formation Bhd fell 11% in active trade in early Thursday, after the company said it is planning a 20-to-1 share consolidation as well as free warrants.

Trading ideas: Globaltec Formation, Hengyuan, manufacturing and plantation companies

KUALA LUMPUR: JF Apex Research believes Globaltec Formation Bhd, Hengyuan Refining Co Bhd, manufacturing and plantation companies are among the stocks to watch on Thursday.

Globaltec plans share consolidation

PETALING JAYA: Globaltec Formation Bhd is proposing to undertake the consolidation of every 20 existing ordinary shares in Globaltec into one ordinary share in Globaltec held on an entitlement date to be determined later.
5220 BSMAF 1818

7-Eleven, Affin Bank, Gabungan AQRS, Hengyuan, XOX, Nylex, Ancom, Utusan, Globaltec, Censof and DNeX

2018-09-05 theedgemarkets
KUALA LUMPUR (July 5): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 6) may include: 7-Eleven Malaysia Holdings Bhd, Affin Bank Bhd, Gabungan AQRS Bhd, Hengyuan Refining Co Bhd, XOX Bhd, Nylex (Malaysia) Bhd, Ancom Bhd, Utusan Melayu (Malaysia) Bhd, Globaltec Formation Bhd, Censof Holdings Bhd and Dagang NeXchange Bhd (DNeX).
5226 5754 4456 PSKXF 5220 PHSXY PSE BCOR 5195

Globaltec plans 20-to-1 share consolidation, free warrants

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): Globaltec Formation Bhd plans to consolidate the company's shares on the basis of 20 shares held on an entitlement date to be fixed, into one share, which could raise its share price to 90 sen from 4.5 sen now.
5220 BSMAF 1818

Globaltec shares suspended for an hour

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): The shares of Globaltec Formation Bhd were suspended for an hour from 3.09pm, as the group announced financial results of its Australia-listed subsidiary NuEnergy Gas Ltd for the quarter ended June 30, 2018.

Trading ideas: Inta Bina, Zelan, Bumi Armada, Globaltec

KUALA LUMPUR: Intan Bina Group Bhd, Zelan Bhd , Bumi Armada Bhd and Globaltec Formation Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.
BRDBF 6501 5220 NNRGF NGY HTHIY 5210

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...